The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Influence of BRAF mutations and RAC1b/RAC1 mRNA expression ratio on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy.
Virginia Alonso-Espinaco
No relevant relationships to disclose
Maribel Marmol
No relevant relationships to disclose
Vicente Alonso
No relevant relationships to disclose
Pilar Escudero
No relevant relationships to disclose
Carlos Horndler
No relevant relationships to disclose
Javier Ortego
No relevant relationships to disclose
Rosa Gallego
No relevant relationships to disclose
Xabier Garcia-Albeniz
No relevant relationships to disclose
Pedro Jares
No relevant relationships to disclose
Miriam Cuatrecasas
No relevant relationships to disclose
Juan Jose Lozano
No relevant relationships to disclose
Antoni Castells
No relevant relationships to disclose
Joan Maurel
No relevant relationships to disclose